Hospital
Bon Secours ST Francis Medical Center LLC
Bon Secours ST Francis Medical Center LLC was paid $44.86M by Medicaid between Jan 2018 and Dec 2024, across 324 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoBON SECOURS ST FRANCIS MEDICAL CENTER LLC
MIDLOTHIAN, VA 23114
MIDLOTHIAN, VA 23114
33aNPI1447212592assigned 04/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.86M
24GClaims1,020,874
24DCodes billed324
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#19 of 80
Median peer was paid$14.69M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81,829 | $2.18M | |
| 2019 | 110,906 | $3.22M | |
| 2020 | 90,381 | $3.19M | |
| 2021 | 116,447 | $4.24M | |
| 2022 | 167,321 | $7.07M | |
| 2023 | 238,172 | $12.19M | |
| 2024incomplete | 215,818 | $12.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 49,066 | 43,393 | $8.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 35,776 | 30,918 | $6.50M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 21,489 | 18,400 | $3.89M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.4% | 11,363 | 9,034 | $3.34M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.9% | 35,006 | 25,184 | $3.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 8,891 | 7,863 | $2.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 11,849 | 10,562 | $1.73M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 8,103 | 7,090 | $1.40M |
| G0378 | Hospital observation service, per hour | 1.9% | 6,140 | 3,769 | $847K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 1,844 | 1,612 | $807K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 3,993 | 3,491 | $781K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 2,389 | 2,146 | $633K |
312 more codes
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 1,823 | $598K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 748 | $486K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,501 | $448K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,202 | $405K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,974 | $383K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,524 | $367K |
| 59025 | Fetal non-stress test | <1% | 2,175 | $338K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 242 | $337K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,025 | $336K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,803 | $305K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,882 | $280K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 396 | $280K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,729 | $269K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,339 | $260K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,687 | $236K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,784 | $229K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,464 | $212K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,372 | $206K |
| 93971 | <1% | 2,301 | $200K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,014 | $196K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,814 | $194K |
| 97162 | <1% | 1,483 | $187K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,327 | $187K |
| 70496 | <1% | 631 | $173K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,083 | $164K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,120 | $156K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 740 | $151K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,387 | $130K |
| 72141 | <1% | 806 | $129K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 172 | $120K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 891 | $117K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,313 | $113K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,285 | $110K |
| 80053 | Comprehensive metabolic panel | <1% | 43,040 | $110K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,176 | $109K |
| 97161 | <1% | 1,470 | $107K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,146 | $101K |
| 76830 | Ultrasound, transvaginal | <1% | 1,508 | $96K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,708 | $91K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 198 | $88K |
| 70491 | <1% | 299 | $85K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 558 | $83K |
| 76536 | <1% | 729 | $78K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,661 | $77K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 462 | $70K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,647 | $64K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 582 | $62K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,500 | $59K |
| 93970 | <1% | 431 | $55K | |
| 11043 | <1% | 261 | $53K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,035 | $53K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 254 | $52K |
| 71250 | <1% | 878 | $51K | |
| 76642 | <1% | 487 | $50K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 314 | $47K |
| 12001 | <1% | 234 | $43K | |
| 76801 | <1% | 1,225 | $41K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,509 | $40K |
| 90677 | <1% | 951 | $40K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,677 | $40K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,270 | $37K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,927 | $34K |
| 72100 | <1% | 2,516 | $34K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 398 | $34K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 275 | $32K |
| 71271 | <1% | 311 | $30K | |
| 97116 | <1% | 1,093 | $28K | |
| 97014 | <1% | 729 | $27K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 197 | $26K |
| 97165 | <1% | 615 | $24K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 174 | $23K |
| 83880 | <1% | 3,697 | $22K | |
| 76818 | <1% | 300 | $21K | |
| 73562 | <1% | 3,110 | $21K | |
| 73221 | <1% | 98 | $21K | |
| 72131 | <1% | 380 | $21K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 155 | $20K |
| 73630 | <1% | 2,650 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,068 | $19K |
| 90715 | <1% | 1,012 | $19K | |
| 70498 | <1% | 658 | $18K | |
| 87040 | <1% | 3,385 | $17K | |
| 74018 | <1% | 2,111 | $17K | |
| 90714 | <1% | 709 | $16K | |
| 85379 | <1% | 4,073 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,590 | $15K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,249 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,071 | $15K |
| 73030 | <1% | 1,904 | $14K | |
| 84484 | <1% | 17,729 | $14K | |
| 70486 | <1% | 318 | $14K | |
| 74183 | <1% | 42 | $13K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,190 | $12K |
| 76770 | <1% | 88 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,655 | $12K |
| 76820 | <1% | 300 | $12K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,151 | $11K |
| J3490 | Unclassified drugs | <1% | 9,525 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,302 | $11K |
| 81025 | <1% | 16,800 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 55,045 | $10K |
| 73130 | <1% | 1,717 | $10K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,883 | $10K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 508 | $10K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 98 | $9K |
| 90674 | <1% | 412 | $9K | |
| 90661 | <1% | 469 | $9K | |
| 73610 | <1% | 2,381 | $8K | |
| 90746 | <1% | 186 | $8K | |
| 99218 | <1% | 926 | $8K | |
| 82962 | <1% | 12,372 | $7K | |
| 72050 | <1% | 281 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,683 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 341 | $7K |
| 81001 | <1% | 29,816 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,416 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,188 | $7K |
| G0010 | Administration of hepatitis b vaccine | <1% | 351 | $7K |
| 73502 | <1% | 1,020 | $7K | |
| 99381 | <1% | 53 | $6K | |
| 86850 | <1% | 2,780 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,983 | $6K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 260 | $6K |
| 90647 | <1% | 784 | $6K | |
| 10060 | <1% | 44 | $5K | |
| 77080 | <1% | 106 | $5K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 184 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,478 | $5K |
| 76870 | <1% | 49 | $5K | |
| 86900 | <1% | 3,554 | $5K | |
| 84145 | <1% | 900 | $4K | |
| 83605 | <1% | 3,823 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 116 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,973 | $4K |
| 90723 | <1% | 622 | $4K | |
| 12011 | <1% | 28 | $4K | |
| 90681 | <1% | 579 | $4K | |
| 90651 | <1% | 265 | $4K | |
| 90716 | <1% | 289 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,904 | $4K |
| 90633 | <1% | 577 | $4K | |
| 80050 | General health panel | <1% | 738 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,521 | $3K |
| 73700 | <1% | 44 | $3K | |
| 90686 | <1% | 682 | $3K | |
| 85027 | <1% | 2,930 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 69 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 384 | $3K |
| 96376 | <1% | 5,216 | $3K | |
| 10061 | <1% | 13 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,484 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,624 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,117 | $3K |
| 85610 | <1% | 4,588 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,797 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,721 | $2K |
| 86901 | <1% | 3,552 | $2K | |
| 83735 | <1% | 10,623 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,396 | $2K |
| 90670 | <1% | 289 | $2K | |
| 85730 | <1% | 1,868 | $2K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,337 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,584 | $2K |
| 73110 | <1% | 999 | $2K | |
| 80047 | <1% | 367 | $2K | |
| 90707 | <1% | 259 | $2K | |
| 99385 | <1% | 15 | $2K | |
| 97016 | <1% | 54 | $2K | |
| 85018 | <1% | 753 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,878 | $2K |
| 73080 | <1% | 446 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,140 | $2K |
| 74240 | <1% | 14 | $2K | |
| 87070 | <1% | 6,255 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,859 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,364 | $2K |
| 90734 | <1% | 223 | $2K | |
| 99152 | <1% | 932 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,830 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,831 | $2K |
| 99383 | <1% | 12 | $1K | |
| 90698 | <1% | 235 | $1K | |
| 81003 | <1% | 2,309 | $1K | |
| 88307 | <1% | 172 | $1K | |
| 86140 | <1% | 1,847 | $1K | |
| 83690 | <1% | 15,356 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,553 | $1K |
| 80143 | <1% | 766 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,172 | $1K |
| 80179 | <1% | 700 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,544 | $1K |
| 84703 | <1% | 1,068 | $967.38 | |
| 80061 | Lipid panel | <1% | 510 | $903.11 |
| 73590 | <1% | 291 | $857.87 | |
| 90700 | <1% | 130 | $848.67 | |
| 87210 | <1% | 2,098 | $818.69 | |
| 87634 | <1% | 537 | $775.93 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,301 | $710.84 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,769 | $705.36 |
| 77062 | <1% | 24 | $664.56 | |
| 90710 | <1% | 87 | $654.46 | |
| 87077 | <1% | 2,397 | $623.77 | |
| 99406 | <1% | 35 | $579.29 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 63 | $557.74 |
| 73140 | <1% | 293 | $535.88 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 79 | $527.85 |
| 72072 | <1% | 59 | $495.44 | |
| 84100 | <1% | 1,960 | $471.31 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,261 | $442.61 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,388 | $436.70 |
| 74019 | <1% | 110 | $402.45 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 18 | $387.46 |
| 87186 | <1% | 2,190 | $369.62 | |
| 90694 | <1% | 55 | $362.91 | |
| 84702 | <1% | 2,344 | $361.76 | |
| 80305 | <1% | 57 | $352.20 | |
| 82077 | <1% | 2,295 | $349.03 | |
| 87205 | <1% | 354 | $343.29 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 707 | $337.67 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,889 | $312.62 |
| 71101 | <1% | 121 | $311.16 | |
| 85652 | <1% | 1,077 | $295.68 | |
| 94761 | <1% | 2,870 | $294.82 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 224 | $288.05 |
| 90696 | <1% | 37 | $281.22 | |
| 80076 | <1% | 89 | $264.65 | |
| C1776 | Joint device (implantable) | <1% | 15 | $258.95 |
| 98960 | <1% | 100 | $250.77 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 512 | $227.65 |
| 0100U | <1% | 18 | $226.40 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 571 | $221.04 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,565 | $200.54 |
| 73090 | <1% | 167 | $195.96 | |
| 82553 | <1% | 79 | $189.32 | |
| 90653 | <1% | 132 | $174.78 | |
| 94760 | <1% | 474 | $167.62 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 818 | $165.80 |
| 84112 | <1% | 14 | $162.93 | |
| 82565 | <1% | 151 | $156.81 | |
| 87807 | <1% | 600 | $134.05 | |
| 88304 | <1% | 303 | $122.64 | |
| 51701 | <1% | 18 | $109.55 | |
| 72040 | <1% | 43 | $109.39 | |
| 82550 | <1% | 1,500 | $109.35 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 698 | $104.23 |
| 29125 | <1% | 60 | $100.00 | |
| 87147 | <1% | 1,453 | $94.86 | |
| 82570 | <1% | 200 | $82.99 | |
| 73560 | <1% | 19 | $79.97 | |
| 90473 | <1% | 65 | $67.82 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 981 | $66.07 |
| 84156 | <1% | 99 | $63.51 | |
| 83615 | <1% | 50 | $60.07 | |
| 81002 | <1% | 254 | $57.89 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 934 | $54.46 |
| 82607 | <1% | 92 | $45.58 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,287 | $41.84 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 514 | $41.75 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,060 | $41.19 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 738 | $38.95 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 770 | $34.49 |
| 94762 | <1% | 247 | $25.63 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 799 | $20.62 |
| 84439 | <1% | 77 | $18.58 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 285 | $16.91 |
| 83550 | <1% | 45 | $15.55 | |
| 87088 | <1% | 222 | $14.41 | |
| 83540 | <1% | 44 | $11.97 | |
| 82150 | <1% | 16 | $11.94 | |
| 82728 | <1% | 30 | $11.66 | |
| 82803 | <1% | 631 | $10.97 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 63 | $10.21 |
| 86580 | <1% | 63 | $9.30 | |
| 86308 | <1% | 43 | $6.55 | |
| A9270 | Non-covered item or service | <1% | 2,092 | $4.99 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 67 | $2.78 |
| 82272 | <1% | 85 | $2.70 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 400 | $1.94 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 14 | $1.17 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 413 | $0.98 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 387 | $0.34 |
| A4565 | Slings | <1% | 118 | $0.26 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 552 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 237 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 183 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 176 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 138 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 138 | $0.00 |
| 76937 | 0% | 13 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 14 | $0.00 |
| 96367 | 0% | 38 | $0.00 | |
| 82947 | 0% | 17 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| 84295 | 0% | 15 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 343 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 63 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 72 | $0.00 |
| C1769 | Guide wire | 0% | 151 | $0.00 |
| 88342 | 0% | 146 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 790 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 113 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 91 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 72 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 52 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 218 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 108 | $0.00 |
| 84132 | 0% | 35 | $0.00 | |
| 82746 | 0% | 32 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 74 | $0.00 |
| 82330 | 0% | 48 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 13 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.